Supernus Pharmaceuticals Inc (SUPN)

Pretax margin

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Earnings before tax but after interest (EBT)	US$ in thousands	97,870	2,769	60,743	73,175	168,648
Revenue	US$ in thousands	661,817	607,521	673,056	560,079	500,962
Pretax margin		14.79%	0.46%	9.02%	13.07%	33.66%

December 31, 2024 calculation

Pretax margin = EBT ÷ Revenue
= $97,870K ÷ $661,817K
= 14.79%

The pretax margin of Supernus Pharmaceuticals Inc has exhibited significant fluctuations over the last five years. In December 2020, the pretax margin stood at a robust 33.66%, demonstrating strong profitability before tax expenses. However, there was a notable decline in the pretax margin to 13.07% by December 2021, indicating a decrease in profitability. This downward trend continued into December 2022 with a pretax margin of 9.02%, suggesting further challenges in maintaining profitability.

The company faced a significant downturn in December 2023 with a pretax margin of a mere 0.46%, indicating a substantial decrease in profitability, potentially due to increased expenses or a decline in revenue. However, in December 2024, there was a notable recovery in the pretax margin to 14.79%, showing signs of improvement in profitability.

Overall, the pretax margin of Supernus Pharmaceuticals Inc has been volatile, with fluctuations reflecting changes in the company's ability to generate profits before accounting for tax expenses. It is essential for the company to closely monitor and manage its expenses and revenue generation to ensure sustainable profitability in the future.